{"id":"W4387142310","doi":"10.1136/ijgc-2023-esgo.507","title":"#66 Survival of PARP inhibitor (PARPi) naïve ovarian cancer patients with a BRCA-mutation receiving maintenance olaparib after chemotherapy for first recurrence. An exploratory analysis of the solo2/engot-ov21 trial","year":2023,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; Medicine; PARP inhibitor; Internal medicine; Oncology; BRCA mutation; Placebo; Ovarian cancer; Chemotherapy; Maintenance therapy; Cancer; Poly ADP ribose polymerase; Biology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001563525,0.0005123187,0.001093258,0.0001790167,0.0002139506,0.0009979974,0.0003392588,0.0007525543,0.002979807],"category_scores_gemma":[0.001434475,0.00024335,0.003176085,0.0003345043,0.0003520501,0.0007873151,0.0003128042,0.001696066,0.0003538853],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004861442,"about_ca_system_score_gemma":0.0005875581,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008624335,"about_ca_topic_score_gemma":0.002288184,"domain_scores_codex":[0.9994484,0.0003019675,0.00003144465,0.00008538141,0.00003484213,0.00009808052],"domain_scores_gemma":[0.9993148,0.0002142075,0.00014658,0.00007752269,0.00003313807,0.0002137955],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8801145,0.001531605,0.03879858,0.0009697507,0.007788537,0.0002352865,0.000118739,0.00226238,0.005147536,0.000427808,0.005489228,0.05711591],"study_design_scores_gemma":[0.4189204,0.2405685,0.2892413,0.0005755413,0.02512899,0.0007644036,0.0002454091,0.004469999,0.002255927,0.002438587,0.01525174,0.0001393276],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9867247,0.007529318,0.0002527284,0.0007071538,0.000239491,0.0001536167,0.002266672,0.00002524922,0.002101067],"genre_scores_gemma":[0.9922397,0.001920041,0.0001796966,0.0006851933,0.0002852391,0.0001222512,0.002685269,0.00001132249,0.001871367],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002979807,"threshold_uncertainty_score":0.00996846,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03684156069980245,"score_gpt":0.3359133151894682,"score_spread":0.2990717544896658,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}